BioVie: Cautiously Optimistic Ahead Of Phase 3 Alzheimer's Data Unblinding
Seeking Alpha,
Summary Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy.
Summary Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy.
Summary BioVie is set to report topline data from its Phase 3 trial in Alzheimer's disease, with a high likelihood of reaching…
Summary Cassava Sciences' results for mild Alzheimer's disease are better than placebo at 12 months but little better beyond…
Follow Summary Cassava Sciences' phase 2 data was from a nonrandomized trial, therefore unconvincing.